Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of $(18.60) per share from the same period last year. The company reported quarterly sales of $3.227 million which beat the analyst consensus estimate of $1.750 million by 84.40 percent. This is a 123.01 percent increase over sales of $1.447 million the same period last year.